Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 2/20 | 0.39 |
| ▸ | RARB | P10826 | 2/20 | 0.39 |
| ▸ | RARG | P13631 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6592969 | 0.91 | NPC1 (0.36) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL6591282 | 0.91 | MAPT (0.34) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL6588869 | 0.90 | CYP3A4 (0.53) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL6591025 | 0.89 | KMT2A (0.33) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL5669671 | 0.89 | RARB (0.41) | RARARARBRARGCYP3A4 | |
| SCHEMBL6234971 | 0.84 | PDK2 (0.38) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL6590616 | 0.82 | CYP3A4 (0.35) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL6596588 | 0.80 | CYP3A4 (0.49) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL6590257 | 0.78 | RARA (0.43) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL6239862 | 0.78 | RARA (0.49) | RARARARBRARGCYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180320139-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL INC. | 2018-11-08 | — | — | US | disclosed |
| US-20160097037-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD. | 2016-04-07 | — | — | US | disclosed |
| US-9271946-B2 | Use of a RAR antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects | Io Therapeutics, Inc. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20110033427-A1 | Expansion Of Renewable Stem Cell Populations | GAMIDA CELL LTD. (IL) | 2011-02-10 | — | — | US | disclosed |
| EP-1558235-B1 | METHODS OF TREATMENT DURING VASCULAR PROCEDURES | ALLERGAN INC (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20080214652-A1 | Methods of treating hyperlipidemia | ALLERGAN SALES, INC. | 2008-09-04 | — | — | US | disclosed |
| EP-1392284-B1 | METHODS OF TREATING HYPERLIPIDEMIA | ALLERGAN INC (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1920771-A2 | Methods of treating hyperlipidemia | Allergan, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20070054882-A1 | Male anti-fertility agents | KLEIN ELLIOTT S | 2007-03-08 | — | — | US | disclosed |
| US-7105566-B2 | Methods of treatment during vascular procedures | ALLERGAN, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20030144256-A1 | Male anti-fertility agents | ALLERGAN SALES, INC. | 2003-07-31 | — | — | US | disclosed |
| US-6521641-B1 | Retinoic acid receptor antagonists or inverse agonists; reversibly inhibiting or preventing spermatogenesis | ALLERGAN, INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020193403-A1 | Methods of treating hyperlipidemia | ALLERGAN SALES, INC. (US) | 2002-12-19 | — | — | US | disclosed |
| WO-2002089781-A2 | METHODS OF TREATING HYPERLIPIDEMIA | ALLERGAN INC. (US) | 2002-11-14 | — | — | WO | disclosed |
| EP-1119350-A2 | RAR ANTAGONISTS AS MALE ANTI-FERTILITY AGENTS | Allergan Sales, Inc. (US) | 2001-08-01 | — | — | EP | disclosed |
| US-6218128-B1 | DRUG SCREENING FOR INVERSE AGONIST BY MONITORING BINDING OF TWO POLYPEPTIDES HAVING SPECIFIC DOMAINS IN PRESENCE OF TEST COMPOUND | ALLERGAN SALES, INC. | 2001-04-17 | — | — | US | disclosed |
| EP-1042313-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST LIKE ACTIVITY | Allergan Sales, Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000019990-A2 | RAR ANTAGONISTS AS MALE ANTI-FERTILITY AGENTS | ALLERGAN SALES, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
| US-5958954-A | 2,2-DIALKYL-4-ARYL-SUBSTITUTED BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES | ALLERGAN SALES, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| WO-1999033821-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST-LIKE ACTIVITY | ALLERGAN SALES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054882-A1 | Male anti-fertility agents | NASP, ALPG, MAN2B2 | RARA 1552/4885RARB 1486/4885RARG 915/4885 |
| US-20080214652-A1 | Methods of treating hyperlipidemia | LDLR, NR1H3, NR1H2 | RARA 37/4885RARB 40/4885RARG 32/4885 |
| US-20020193403-A1 | Methods of treating hyperlipidemia | LDLR, NR1H3, NR1H2 | RARA 37/4885RARB 40/4885RARG 32/4885 |
| US-20030144256-A1 | Male anti-fertility agents | NASP, ALPG, MAN2B2 | RARA 1552/4885RARB 1486/4885RARG 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.